AQ312 / Aqilion - LARVOL DELTA

AQ312, A POTENT SMALL MOLECULE ARYL HYDROCARBON AGONIST, DEMONSTRATES EFFICACY IN EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE (UEGW 2024) - "AQ312 is a potent and selective small molecule AhR agonist that is rapidly cleared in rodents. The molecule has demonstrated therapeutic benefit in 2 models of experimental colitis. AQ312 has the potential to be the ‘best in class’ AhR agonist for the treatment of IBD."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CYP1A1

PRECLINICAL DEVELOPMENT OF AQ312, A POTENT AND SELECTIVE SMALL MOLECULE ARYL HYDROCARBON AGONIST, FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE. (DDW 2024) - "We have developed AQ31 a potent and selective small molecule AhR agonist that is rapidly cleared in rodents. The molecule has demonstrated therapeutic benefit in models of experimental colitis. AQ31 has the potential to be the '˜best in class' AhR agonist for the treatment of IBD by reducing inflammation and enhancing mucosal barrier integrity."

Preclinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD4 • CYP1A1

Aqilion strengthens its pipeline with a drug candidate in chronic inflammatory bowel disease, IBD [Google translation] (Cision) - "Aqilion has nominated Girtab, a program from the company's research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory bowel disease. Girtab complements Aqilion's pipeline well and strengthens the company's strategic focus on drug targets and programs with great potential in inflammatory diseases."

Clinical • Inflammatory Bowel Disease